1 / 10

A Opening in the Market

A Opening in the Market. Why develop a new PAH drug. Pulmonary Arterial Hypertension. Increase in pulmonary arterial resistance and pressure Pathophysiology: vasoconstriction, thickening and occlusion of pulmonary arteries and arterioles Symptoms: Shortness of breath

brooklyn
Download Presentation

A Opening in the Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Opening in the Market Why develop a new PAH drug

  2. Pulmonary Arterial Hypertension • Increase in pulmonary arterial resistance and pressure • Pathophysiology: vasoconstriction, thickening and occlusion of pulmonary arteries and arterioles • Symptoms: • Shortness of breath • Decreasing exercise tolerance • Right heart failure • Marked functional limitation • Right side of the lungs becomes enlarged

  3. Inhaled Nitrite Decrease Pulmonary Arterial Hyperplasia Normal artery Artery with PAH Treated artery

  4. Prevalence/ Treatment • Fatal outcome: <3 yrs (w/o treatment) 5-7 yrs (w/ treatment) • US prevalence: 50,000-100,000 (est) 16,500 diagnosed & treated • Three main classes of drugs- each targets different pathway • This allows for combination therapy • PAH is a growing niche market • New drugs have been approved, but there is still room for improvement • efficacy and safety

  5. PAH Market • Global Market worth approx. 3.3 billion • grew due to: • drug development activity • increased awareness • Limited Market • High intensity leads to competition

  6. Current PAH Treatments

  7. Why Aironite? • Identified nitrite (NO pro-drug) technology at the NIH and felt it had great potential • Nitric oxide approved in pediatric pulmonary hypertension • Newly recognized nitrite biology • Animal & human data support further development • Pulmonary specific vasodilator and delivery system; minimal, if any, side effects • Compare to Traceleer • Current therapies are not curative; median survival improved from 3+ to 5+years. New drugs are needed. • Expect additive or synergisitic efficacy when combined with oral and inhaled Rx targeting other pathways (prostacyclin, endothelin) • Possibility of one dose a day • Convenient and cost effective

  8. Why Aironite? • Current therapies are not curative; median survival improved from 3+ to 5+years. New drugs are needed.

More Related